ELISA Complement Activity Analysis

Product name

C5a MicroVue™ Quidel®

Measurement of terminal complement pathway activation in experimental samples

Cat-Nr.A025
Range0.1 - 1 ng/ml
SensitivityLOD: 0.01 ng/ml; LLOQ: 0.050 ng/ml
Incubation time2 hours 15 minutes
Sample volume20 µl (dilute 1:20 for plasma); 10 µl (dilute 1:50 for serum)
Sample type

Serum, EDTA- and citrated plasma.

Sample preparation

The proper collection, storage and shipment of specimens are essential. Test immediately or stored up to 4 hours at 2-8 ºC or on ice. For longer-term storage the samples should kept frozen at -70 ºC with stabilizing solution (Cat. No. A9576), dilute samples 1:1 with stabilizing solution.

Reference values

EDTA Plasma      0.37 – 74.33 ng/ml
Serum              13.37 – 179.23 ng/ml

Species

Human

Specificity

C5a and C5a des-Arg

Tests96
MethodELISA
Intended use

C5a is generated as a result of cleavage of the terminal complement protein C5,during activation of the complement system via the classical, alternative or lectin pathway. C5a is a low molecular weight (approximately 9 kD) protein fragment of 74 amino acids. C5 a is rapidly metabolized by the serum enzyme carboxypeptidase to more stable, less active, 73 amino acid form, C5a des-Arg.

Research has associated elevated levels of fluid phase and adsorbed C5a with hemo-incompatibility of some biomaterials, particularly in extracorporeal circuits. Levels of C5a have also been associated with pathogenesis of a variety of disease states, including myocardial infarction, stroke, as well as vascular leak syndrome and associated kidney injury. The role of C5a in the pathogenesis of malaria and other infectious diseases, as well as sepsis, is likewise well documented. 

Product informations

Back to overview